<DOC>
	<DOCNO>NCT00027027</DOCNO>
	<brief_summary>The purpose Phase I study test safety rhuMAb 2C4 see effect ( good bad ) patient certain type cancer , also find high dose rhuMAb give without cause severe side effect . All study participant assign specific group evaluate different dosage rhuMAb 2C4 . The study schedule run one year depend patient respond study treatment .</brief_summary>
	<brief_title>Safety Study rhuMAb 2C4 Treat Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Signed informed consent Age &gt; =18 year old ECOG performance status 0 1 ( see Appendix F ) Life expectancy &gt; =12 week Histologically document , incurable , locally advanced metastatic solid malignancy Disease progression standard effective therapy malignancy standard therapy At least one bidimensionally measurable lesion ( &gt; =2 cm [ &gt; =1 cm spiral CT scan ] ) HER2negative status define fluorescence situ hybridization ( FISH ) test ( subject breast cancer ) Use effective mean contraception woman childbearing potential Granulocyte count &gt; =1500/uL , platelet count &gt; =100,000/uL , hemoglobin &gt; =9 g/dL Serum bilirubin less equal upper limit normal ( ULN ) alkaline phosphatase , AST , ALT &lt; =2.5x ULN ( ALT AST &lt; =5x ULN subject liver metastasis ; alkaline phosphatase &lt; =5x ULN subject liver bone metastasis ) Serum creatinine less equal ULN creatinine clearance &gt; =60 mL/min International normalize ratio ( INR ) &lt; 1.3 activate partial thromboplastin time ( aPTT ) &lt; 1.5x ULN Pleural effusion , ascites , bone lesion manifestation current cancer Symptomatic untreated brain metastasis Prior chemotherapy , hormonal therapy ( except androgendeprivation therapy subject prostate cancer ) , radiotherapy , immunotherapy within 4 week Day 1 ( within 6 week nitrosoureas mitomycin ) Prior treatment Herceptin Prior cumulative doxorubicin dose &gt; 360 mg/m2 equivalent History malignancy within 5 year Day 1 except adequately treat carcinoma situ cervix basal squamous cell skin cancer History significant cardiac disease , unstable angina , congestive heart failure , myocardial infarction , ventricular arrhythmia require medication Ejection fraction &lt; 50 % low limit normal determine ECHO ( Subjects unable ejection fraction evaluate ECHO may ejection fraction evaluate MUGA scan , although must discuss Medical Monitor prior enrollment . ) Active infection require IV antibiotic Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) Clinically important history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus ( HIV ) infection Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication Major surgery significant traumatic injury within 3 week Day 1 Pregnancy lactation Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>